Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Eli Lilly and Co (NYSE:LLY)

Delayed Data
As of Oct 05
 -0.95 / -1.09%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Major

Company Description

Eli Lilly & Co. discovers, develops, manufactures and sells pharmaceutical products. The company operates through the following business segments: Human Pharmaceutical Products and Animal Health. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular, and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The Other Pharmaceuticals products include anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services. Its products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. Eli Lilly was founded by Colonel Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Contact Information

Eli Lilly & Co.
Lilly Corporate Center
Indianapolis Indiana 46285
P:(317) 276-2000
Investor Relations:



Mutual fund holders37.32%
Other institutional28.92%
Individual stakeholders12.16%

Top Executives

John C. LechleiterChairman, President & Chief Executive Officer
Derica W. RiceChief Financial Officer & EVP-Global Services
Thomas F. BumolSenior VP-Biotechnology & Autoimmunity Research
Jan M. LundbergExecutive Vice President-Science & Technology
Timothy J. GarnettChief Medical Officer